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Abstract
Ventilator-associated pneumonia (VAP) is a pulmonary infection that appears after 2 
days of endotracheal intubation and when invasive mechanical ventilation is used. VAP 
is considered the most common nosocomial infection in the intensive care unit (ICU) 
and presents high morbidity and mortality rates, principally when caused by multi-
resistant bacteria. Several risk factors are associated with VAP, including the micro-
biota, advanced age, immunocompromising conditions, pulmonary illness, length of 
mechanical ventilation, the aspiration technique, tracheostomy, supine positioning, 
enteral feeding, previous antibiotic exposure, among other endogenous and exog-
enous factors. The main pathogens are Staphylococcus aureus, Pseudomonas aeruginosa, 
Acinetobacter baumannii, and Enterobacteriaceae members, which are considered poten-
tially multidrug-resistant pathogens. Conventional microbiology methods continue to 
be used for laboratory diagnosis. However, it is necessary to validate rapid and accu-
rate laboratory methods, such as molecular assays that detect multiple gene sequences 
of a wide range of bacterial species and resistance markers. Therefore, the objective of 
this chapter is to review and update several aspects related to VAP, including risk 
factors, etiology, laboratory diagnosis,  bacterial virulence and VAP severity, and anti-
biotic susceptibility.
Keywords: ventilator-associated pneumonia, respiratory infections, nosocomial 
infections, microbiology
1. Introduction
Pneumonia is a serious public health problem associated with high morbidity and mortality 
rates that leads to a significant increase in healthcare costs. It results from an infectious pro-
cess of the lower airways through aspiration or inhalation of pathogenic microorganisms. It 
can be acquired in the community or in the hospital environment, after 48 h of admission [1]. 
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Hospital-acquired infections usually have a high mortality rate (approx. 20%) when compared 
to the community acquisition (10%), this rate increases even more when it is associated with 
mechanical ventilation [2].
According to the guidelines of the American Thoracic Society, hospital pneumonia is divided 
into ventilator-associated pneumonia (VAP), which develops after 48–72 h of endotracheal intu-
bation and the one that occurs in nonhospitalized patients, but that have constant contact with 
health services [3]. VAP is the infection of the pulmonary parenchyma with onset after 48–72 
h of endotracheal intubation. Early-onset VAP occurs during the first 4 days of mechanical 
ventilation, whereas late-onset VAP occurs on 5 or more days of mechanical ventilation [4–7]. 
VAP corresponds to 70–80% of cases of hospital-acquired pneumonia in intensive care units [1].
VAP is characterized by the presence of new or progressive pulmonary infiltrates, systemic 
alterations such as fever and leukocyte alterations, altered sputum, and diagnosis of an infec-
tious agent [8]. Mortality due to VAP is high, principally because of the association with 
 multidrug-resistance (MDR) bacteria [9]. In pediatrics and neonatology, the frequency of VAP 
is 3–19%, with a mortality rate ranging from 10 to 20% of patients [10].
Many microorganisms can be involved in VAP. In this chapter, data on microbiology of VAP 
are reviewed, including risk factors, etiology, virulence features of main pathogens contribut-
ing to VAP severity, antimicrobial susceptibility, and laboratory diagnosis.
2. Risk factors for VAP
The use of mechanical ventilation is a significant risk factor for hospital-acquired pneumo-
nia associated with aspiration, lowering of consciousness level, excessive management and 
patient transport, and chronic lung disease. The risk of VAP increases by 3% in the first 5 days 
of ventilation, 2% in 5–10 days, and 1% in 10 days of ventilation [11].
Although other routes may lead to VAP, such as hematogenous spread, inhalation of con-
taminated air, and also by extension of an infection of the pleural space, the main entry of 
pathogens into the lower respiratory tract occurs by aspiration of secretions containing micro-
organisms (from oropharynx or reflux of the stomach). Pathogens that cause VAP may be part 
of the upper airway microbiota or are acquired exogenously after hospital admission [8].
Figure 1 shows the different risk factors that are associated with VAP. Among risk factors 
inherent to the host (endogenous), it was observed that patients with advanced age, immu-
nosuppressed individuals or pulmonary diseases have an increased risk for the development 
of VAP [4, 12, 13]. In a multicenter cohort study that analyzed the frequency of VAP among 
middle-aged, elderly, and very elderly patients, it was concluded that the highest frequency 
of VAP was in elderly patients (16.6%), associated to increased mortality among the elderly 
and very elderly (51%) when compared to middle-aged patients (35%) [4].
Long-term mechanical ventilation in patients with acute respiratory distress syndrome 
(ARDS) increases the risk of VAP [5]. Evaluation of the association between ARDS and VAP 
found that 55% of patients with ARDS developed nosocomial infection compared to 28% 
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without the syndrome [14]. Cigarette smoking, inhibition of mucociliary function, and reduc-
tion of cough reflex due to obstruction of airflow make chronic obstructive pulmonary disease 
(COPD) patients more susceptible to ventilation-associated infections [5].
The exogenous risk factors are due to the interventions undergone by the patient in intensive 
care units (ICUs) (Figure 1). Mechanical ventilation equipment is a primary source of infec-
tion, in which respiratory circuit condensations can be sources of microorganisms [8]. The 
endotracheal tube, as well as other invasive devices, promotes bacterial colonization of the 
trachea. Bacteria may have access to the lower respiratory tract through a partial blockage 
around the cuff or through the lumen of the endotracheal tube.
Prolonged intubation may promote the formation of a layer of microorganisms adhered to 
the inner surface of the endotracheal tube. This formation, known as biofilm, represents an 
important virulence mechanism and contributes to pathogen persistence as well as therapeu-
tic failures, since microorganisms in the biofilm state are more resistant to host defenses and 
also metabolically less active, therefore, are more resistant to antibiotics [8, 15]. To inhibit the 
biofilm formation on the surface of polymeric medical devices, many studies have focused on 
the development of new biomaterials with modifications that alter the biophysical interac-
tions of the cell surface or impede biofilm growth. A wide range of new coatings with anti-
microbials, cationic antimicrobial peptides, or metal nanoparticles (e.g., copper, gold, iron, 
Figure 1. Main endogenous and exogenous risk factors for VAP.
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magnesium, silver, titanium, or zinc) have been applied to medical devices such as endotra-
cheal tubes [16, 17]. Other approach consists in the use of polymers that exhibit antimicrobial 
activity by themselves, with positively charged active groups (biguanide, cyclic N-halamine, 
quaternary ammonium, pyridinium or phosphonium salts, and polyionenes) or other poly-
mers, such as synthetic poly(phenylene ethynylenes), polynorbornenes, and polymethacry-
lates that display similar antimicrobial activities of human peptides [17]. Both types of devices 
display advantages and disadvantages, but in the near future one expects to have nontoxic 
and biocompatible products available, which display broad-spectrum antibiofilm activities 
for the prevention of biofilm formation on endotracheal tubes [18].
The aspiration technique of endotracheal secretions also plays an important role as a risk 
factor for the establishment of VAP. The open method where a sterile aspiration probe is 
introduced has disadvantages such as loss of oxygenation, since the patient is temporarily 
disconnected from the ventilator and the system is opened with exposure of the patient, and 
the maximum duration of use of each circuit is not known [5].
Tracheostomy is an indicated procedure after 2 weeks of translaryngeal intubation of critically 
ill patients. Apparently, early tracheostomy may be associated with a lower incidence of pneu-
monia when compared to the late procedure or nonprocedure [19]. Frequent reintubations are 
also associated with VAP because of the risk of aspiration of gastric contents through the use 
of the nasogastric tube, subglottic dysfunction, and lowering of the level of consciousness [5].
The VAP prevention guidelines recommend the placement of the patient in the bed between 
30 and 45° semi-reclined [20]. The supine position to which the patient is subjected may 
lead to lesions such as atelectasis in the dorsal lung region, barotrauma in the ventral 
lung region [5]. Experiments performed on rats proved the advantage of lateral decubitus 
in improving gas exchange, reducing gastroesophageal reflux, and avoiding pulmonary 
infection by gastric aspiration due to gravity [21]. Recently, the semi-decubitus position 
(30–60°) was shown to reduce the risk of VAP compared to supine positioning (0–10°) [20].
Nasal feeding by nasogastric tube increases gastric secretions and pH, leading to colonization 
by Gram-negative bacilli. Aspiration of this gastric content increases the risk of VAP. The use 
of sedative medications used in therapeutic procedures can cause prolonged relaxation of the 
muscles, increasing the risk of aspiration [5].
In addition, in the neonatal intensive care unit (NICU), some risk factors are associated with 
characteristics peculiar to this age group, including: length of stay in the NICU, enteral and 
parenteral feeding, blood transfusion, low birth weight, prematurity, and bronchopulmonary 
dysplasia [10, 13].
3. Etiology of VAP
VAP is usually caused by bacteria, whereas fungi and viruses are rarely involved [3, 6]. 
Generally, early-onset VAP is caused by pathogens more susceptible to antibiotics, including 
Streptococcus pneumoniae, Haemophilus influenzae, and methicillin-susceptible Staphylococcus 
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aureus. On the other hand, late-onset VAP is usually caused by antibiotic-resistant bacteria, 
such as Pseudomonas aeruginosa, Acinetobacter spp., methicillin-resistant S. aureus (MRSA), and 
extended-spectrum β-lactamase producing Enterobacteriaceae, such as Klebsiella pneumoniae, 
Escherichia coli, Enterobacter spp., among others [5–7]. However, some studies have reported 
that both susceptible and antibiotic-resistant microorganisms can have similar frequencies in 
early and late-onset VAP [22, 23].
In many cases, VAP can be caused by more than one pathogen (polymicrobial infection). This 
fact can be ignored sometimes when isolates are reported only as a percentage of the total 
number of isolates. In a recent study, performed in medical and surgical ICUs of a hospital in 
Spain, of 147 VAP patients, 32 (21%) had more than one pathogen associated. Interestingly, 
the clinical outcomes were not influenced by the polymicrobial etiology, when appropriate 
antibiotic therapy was administered [24].
The etiology of VAP varies in different countries and even between ICUs of the same city, 
distinct patients groups (like the ARDS patients, immunocompromised, and so on), or set-
tings of the same hospital [25]. However, among Gram-negative bacteria, a high frequency 
is generally reported for P. aeruginosa, Acinetobacter spp., and Enterobacteriaceae members. 
Among Gram-positive isolates, S. aureus and Streptococcus spp. are considered as important 
pathogens [3, 5, 14, 25–27]. Table 1 shows a list of the most frequently and also some uncom-
mon microorganisms detected in VAP patients.
Microorganisms Frequency (%)
(1) Gram-positive bacteria
 Staphylococcus aureus 20–32
 Streptococcus spp. 2–8
 Coagulase-negative staphylococci 1–2
(2) Gram-negative bacteria
 Pseudomonas aeruginosa 20–28
 Acinetobacter spp. 4–13
 Klebsiella pneumoniae 8–12
 Escherichia coli 4–10
 Haemophilus influenzae 4–8
 Enterobacter spp. 6–7
 Serratia spp. 2–4
 Neisseria spp. 2–3
 Stenotrophomonas maltophilia 2–3
(3) Other bacteria <1 each
 Anaerobes
 Corynebacterium spp.
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4. Virulence of major pathogens and VAP severity
Clinical outcomes of VAP depend on a variety of factors, which are inherent to the patient, 
the hospital assistance, and also the microorganism, including host immune system status, 
underlying diseases associated, appropriate antibiotic therapy, accurate and rapid clini-
cal and laboratory diagnosis, antimicrobial susceptibility, and virulence of the pathogen. 
Antimicrobial susceptibility is discussed in Section 5. Here, we present significance of major 
virulence factors associated with VAP severity of four selected pathogens: Acinetobacter baumannii, 
K. pneumoniae, P. aeruginosa, and S. aureus.
4.1. Acinetobacter baumannii
There are more than 20 Acinetobacter species, with A. baumannii being the most commonly 
isolated in clinical settings, in which it represents important emerging nosocomial pathogen. 
A. baumannii is a Gram-negative bacterium, strictly aerobic, nonfermentative coccobacillus, 
nonmotile, nonpigmented, and catalase-positive. It is ubiquitous in nature and has been 
recovered from soil, water, and animals and found as part of the normal skin, throat, and 
rectal flora of human. Although a frequent colonizer, A. baumannii can be the cause of severe 
and sometimes lethal infections, frequently of nosocomial origin, principally VAP. A survey 
in U.S. hospitals showed that the majority of the isolates (57.6%) were from the respiratory 
tract, and Acinetobacter species ranked fifth as the causative organism of VAP (6.6%) [28–30].
In recent years, it has been designated a “red alert” human pathogen and has caused consid-
erable concern in the medical community. This pathogen can adhere to surfaces, and it spe-
cifically targets moist tissues such as mucous membranes or skin that has been exposed due 
to accident or injury, and can cause a wide variety of infections. Most of the cases involve the 
respiratory tract, but bacteremia, meningitis, and wound infection may also occur. A recent 
systematic review and meta-analysis showed that some invasive procedures frequently used 
Microorganisms Frequency (%)
 Enterococcus spp.
 Moraxella spp.
(4) Viruses <1 each
 Influenza virus
 Herpes simplex virus
 Cytomegalovirus
(5) Fungi <1 each
 Aspergillus spp.
 Candida spp.
 Pneumocystis carinii
Table 1. Frequency of etiologic agents of VAP.
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in the ICU increase the risk of A. baumannii bacteremia: mechanical ventilation, central venous 
or urinary catheterization, and nasogastric tube use [31, 32].
The virulence of A. baumannii can be attributed to several factors: capacity to form biofilms; 
its ability to adhere, to colonize, and invade human epithelial cells; its antibiotic resistance 
mechanisms; and its ability to acquire foreign genetic material to promote its own survival 
under antibiotic and host selection pressures. Approximately 30% of Acinetobacter strains also 
produce an exopolysaccharide, which is a major virulence factor protecting bacteria from host 
defenses [28, 31].
4.2. Klebsiella pneumoniae
K. pneumoniae is generally considered an opportunistic pathogen that affects mainly immuno-
compromised individuals. It can be found normally in the intestine, oral cavity, and skin, as 
well as in hospital settings and medical devices [33]. K. pneumoniae is able to form biofilms in 
catheters and endotracheal tubes, which represent major sources of infection in patients with 
invasive devices [34].
Infections by K. pneumoniae that involves biofilm formation tend to be persistent or chronic, 
since the biofilm protects the pathogen of the host immune response and also of the antibi-
otic action [35]. An additional risk factor for chronic infections caused by nosocomial strains 
includes resistance to multiple antibiotics, making difficult for the choice of suitable antibiot-
ics for the treatment [36].
K. pneumoniae has about 78 capsular serotypes (or K antigens) [37]. Some of them present an 
increase in the production of the capsule and present very viscous colonies, which are called 
hypermucoviscous. Such isolates have also been considered to be hypervirulent because cap-
sule is the most important virulence factor of K. pneumoniae [38].
A practical way to check if an isolate is hypermucoviscous is by using the string test. If there 
is the formation of a viscous chain greater than 5 mm after touching bacterial growth on 
agar and try to stretch it with a platinum loop. The degree of mucoviscosity correlates with 
the establishment of invasive infections. Hypervirulent K. pneumoniae is highly invasive and 
can affect previously healthy persons, causing fatal infections, including severe pneumonia 
among them [38]. The bacterium with the phenotype of hypermucoviscosity is capable of 
spreading from one organ to other organs (metastatic spread) [39].
The capsule consists of polysaccharides and is generally constituted by repeating units of three 
to six sugars [38]. The main functions assigned to it include: (1) protection of K. pneumoniae  
against opsonization and phagocytosis [40]; (2) interference with dendritic cells (DCs) mat-
uration and, consequently, in the production of pro-Th1 cytokines mediated by DCs [41]; 
(3) anti-inflammatory effect by the inhibition of IL-8 expression [42–44]; and (4) reduction of 
the amount of antimicrobial peptides reaching the bacterial surface, thus, promoting resis-
tance to them [45].
In addition to capsule, iron acquisition is a virulence property that also contributes to the persis-
tence of the microorganism in the patient body and, consequently, to VAP, since iron is essen-
tial for bacterial growth. Pathogenic members of the Enterobacteriaceae family  usually display 
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a variety of iron uptake systems, of which at least 12 have been described in K. pneumoniae. 
Isolates associated with pulmonary infections also produce yersiniabactin and salmochelin, 
which are not sequestered by the host protein lipocalin 2 of the innate immune defense [46, 
47]. Additionally, hypervirulent K. pneumoniae produces a higher amount and more active sid-
erophore molecules than classical K. pneumoniae, which increases its pathogenic potential [48].
4.3. Pseudomonas aeruginosa
VAP caused by P. aeruginosa has been associated with higher case fatality rates than that by 
other bacteria. This pathogen is a noninvasivefermenting Gram-negative, aerobic, rod-shaped 
polar-flagella, with unipolar motility. P. aeruginosa is considered emerging as an important 
nosocomial pathogen worldwide and is responsible for an extensive spectrum of infections in 
humans associated with significant morbidity and mortality. It is an opportunistic pathogen 
that is normally found in plants, soils, and in a variety of aquatic environments. The adapt-
ability and high antibiotic resistance allow it to survive in a wide range of other natural and 
artificial settings, including surfaces in medical facilities. In addition, P. aeruginosa is recog-
nized for its ability to form biofilms and directly increase the VAP-induced lung injury. In the 
United States, P. aeruginosa is among the most common hospital pathogens and is the second 
most common pathogen isolated from patients with VAP and has been associated with pro-
longed hospitalization, increased cost, and mortality [49–52].
Cell surface virulence factors of P. aeruginosa play an important role in colonization of the 
lower respiratory tract. These factors include flagellum, pili or fimbriae, lipopolysaccharide 
(LPS), as well as type III secretion system (T3SS), which is a major determinant of virulence. 
The T3SS expression is frequently associated with acute invasive infections and has been 
linked to increased mortality in infected patients, and it is shared among many pathogenic 
Gram-negative bacteria as a means of injecting toxins directly into host cells [49, 53].
Additionally, several proteases are produced by P. aeruginosa. These proteases have estab-
lished roles in distinct infectious process, such as hydrolysis of immunoglobulin, fibrin, 
fibrinogen, and also disruption of epithelial tight junctions. Main P. aeruginosa proteases 
include pyocyanin, which induces damage to the respiratory tract, such as epithelial necrosis 
and reduced ciliary movement; pyoverdin, its main secreted siderophore; protease IV, a ser-
ine protease responsible to degradation of complement proteins, fibrinogen, immunoglobulin 
G, and plasminogen; elastase and metalloproteinases that degrade elastin, collagen types III 
and IV, surfactant, immunoglobulins, complement factors, and cytokines; and exotoxin A, 
one of the most potent toxins with cytopathic activity, among others, such as quorum-sensing, 
a very sophisticated gene regulatory mechanism that allows bacteria to coordinate activity 
through the production of small diffusible molecules. These functions include the formation 
of biofilms, motility, secretion of virulent factors, and exopolysaccharide production [49, 54].
4.4. Staphylococcus aureus
S. aureus strains produce several virulence factors that contribute to the pathogenesis and 
severity of lower respiratory infections. Some of them can hinder host defenses, such as  protein 
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A, coagulase, leukocidin, and γ-toxin [55]. Protein A is an important virulence factor in the 
pathogenesis of experimental staphylococcal pneumonia in mice [56]. Moreover, protein A 
mediates: (1) invasion across airway epithelial cells through activation of RhoA GTPase sig-
naling and proteolytic activity; (2) binding to tumor necrosis factor receptor 1 (TNFR1) on 
lung epithelial cells, and (3) activation of a specific intracellular signaling causing the recruit-
ment of neutrophils. These activities increase inflammation of the airway epithelium and, 
thus, contribute to tissue damage [57].
Cysteine proteases, in particular staphopain A (ScpA), cleave the pulmonary surfactant pro-
tein-A (SP-A), a major surfactant component with immune functions that is important during 
S. aureus infections [55]. Additionally, S. aureus releases enzymes with significant roles as 
virulence factors, including proteases, nucleases, lipases, hyaluronidase, and staphylokinase 
that facilitate the invasion of the infected tissue [58].
Interestingly, S. aureus display a great ability to subvert innate and adaptive immune responses 
to favor its replication [59]. In some situations, such as in immunocompromising conditions, 
there is a higher susceptibility to acquire S. aureus infection, mainly by hospitalized patients. In 
this context, S. aureus and especially the epidemic methicillin-resistant S. aureus strains cause 
severe necrotizing pneumonia by producing Panton-Valentine leukocidin (PVL) that has been 
reported to cause rapidly progressive necrosis of the lung tissue in young immunocompetent 
patients. The severity of disease, survival, and clinical outcome of VAP patients can also be 
associated with the presence of the Panton-Valentine leukocidin genes in MRSA [60]. The role 
of PVL in the pathogenesis of MRSA infection is not clear, but recently, it was demonstrated 
that the PVL have strong affinity for host extracellular matrix proteins being, therefore, impli-
cated as a S. aureus adherence molecule. Moreover, PVL as a cytotoxin targets human polymor-
phonuclear neutrophils, and monocytes or macrophages, or both, leading to their apoptosis 
or necrosis as result of the Bax-independent apoptosis occurring by means of a novel pathway 
that presumably involved PVL-mediated pore formation in the mitochondria membranes.
5. Antimicrobial susceptibility and management of patients
Choosing an initial antibiotic for suspected VAP is a difficult task. A scheme of empiric anti-
biotic therapy must take into account that S. aureus, P. aeruginosa, Acinetobacter spp., and 
Enterobacteriaceae members together represent more than 80% of VAP cases worldwide and 
several strains are defined as MDR pathogens [26]. To provide suitable antibiotic exposure 
regarding the possibility of infection by MDR pathogens, the empiric therapy should contain 
multiple agents with broader spectrum of activity [25].
However, antibiotic choices should be based on local prevalence and the antimicrobial sus-
ceptibility profile of the usual pathogens, since data from guidelines or other hospitals can 
be ineffective [61]. For empiric MRSA coverage, vancomycin or linezolid are strongly recom-
mended. On the other hand, if it is indicated as MSSA coverage, the following antibiotics 
should be used: piperacillin-tazobactam, cefepime, levofloxacin, imipenem, or meropenem. 
Suspected etiology for MRSA or MSSA should be based on the presence of risk factors [61].
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It has been reported that more than 50% of MRSA are also resistant to macrolides, lincos-
amides, fluoroquinolones, and aminoglycosides. This high level of resistance not only impedes 
successful therapy but also allows the microorganism to persist in the hospital, expanding 
its reservoir. So, vancomycin is the first-line treatment to VAP patients caused by MRSA. 
Nevertheless, some studies have described S. aureus strains with decreased susceptibility to 
vancomycin (vancomycin intermediate-resistant S. aureus, VISA). The acquired-resistance of 
MRSA to vancomycin is related to acquire mutations that appear in MRSA during vancomy-
cin therapy [62, 63]. More recently, studies describing MRSA strains with high-level vanco-
mycin resistance (vancomycin-resistant S. aureus, VRSA) were described. The mechanism of 
resistance is associated to the presence of transposon Tn1546, acquired from vancomycin-
resistant Enterococcus faecalis, which is known to alter cell wall structure and metabolism, but 
the resistance mechanisms in VISA and VRSA isolates are less well defined [62].
Antibiotic options for Gram-negative coverage are more varied and must contain two anti-
pseudomonal antibiotics from different classes in the presence of risk factors for MDR patho-
gens for the initial treatment of suspected VAP. If the patient does not present risk factors for 
MDR pathogens, only one anti-pseudomonas drug should be prescribed [61].
The frequency of infections caused by P. aeruginosa has increased in combination with the 
morbidity and mortality among hospitalized patients, all of which are exacerbated by anti-
microbial resistance. Studies have demonstrated that resistance to carbapenems, aminogly-
cosides, and fluoroquinolones has increased gradually over the past few years, as well as 
episodes caused by MDR strains. Many P. aeruginosa isolates display an intrinsic reduced sus-
ceptibility to several antibacterial agents, as well as a tendency to develop resistance during 
therapy, especially in carbapenem-resistant strains. The most common mechanism of imipe-
nem resistance in P. aeruginosa is a combination of chromosomal AmpC production and porin 
alterations. It also produces extended-spectrum β-lactamases (ESBLs) and can harbor other 
antibiotic resistance enzymes such as K. pneumoniae carbapenemases (KPC) and imipenem 
metallo-β-lactamases. β-Lactamase production, especially ESBLs, remains the main factor to 
acquired β-lactam resistance [52, 64, 65].
K. pneumoniae may present two major types of antibiotic resistance: (1) expression of ESBLs, 
which make them resistant to cephalosporins and monobactams and (2) the expression of 
carbapenemases that make K. pneumoniae resistant to almost all available β-lactams, including 
carbapenems. The first reported of carbapenemase by K. pneumoniae was in the USA, in 1996, 
which was designated KPC. Currently four classes of carbapenemases (classes A–D) have 
already been described and KPCs are classified into class A. To date, 16 KPC class A vari-
ants have already been identified. In addition to KPCs, K. pneumoniae strains may carry other 
forms of carbapenemases, such as class B metallo-β-lactamases (such as New Delhi's metallo-
β-lactamase NDM-1 enzymes) and OXA class. In addition to β-lactamases, mutations in outer 
membrane proteins (OMPs) may also make the bacterium more resistant to β-lactams, par-
ticularly if it was in combination with the expression of a carbapenemase [66].
A. baumannii is also considered an emerging cause of nosocomial outbreaks, especially by MDR 
strains in ICUs. The most significant mechanism of carbapenem resistance in A. baumannii is 
the production of carbapenemases, which can be either intrinsic or acquired. Carbapenems 
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have been considered the agents of choice for infections caused by susceptible pathogens, but 
the rapid increase in carbapenem resistance rates has complicated this issue. Other mecha-
nisms include: changes in OMPs, penicillin-binding proteins, and efflux pumps; resistance to 
aminoglycosides, mediated by aminoglycoside phosphotransferases, acetyltransferases, and 
adenyltransferases; resistance to quinolones, polymyxins, tetracyclines, among others [28].
A recent cohort study of bacteremia associated with pneumonia found that inappropriate ini-
tial antibiotic treatment seems to be the most important independent determinant of mortality 
and is the only identified mortality predictor amenable to intervention [67]. These Gram-
negative bacteria are responsible for increasing numbers of infections encountered in hospi-
tals, particularly among immunocompromised patients, and community-acquired infections 
are also increasing in prevalence. Furthermore, the impact of P. aeruginosa and A. baumannii 
resistance on health systems is a major concern in hospitals worldwide.
6. Laboratory diagnosis
The diagnosis of VAP is usually based on clinical, radiographic, and microbiological criteria. 
Microbiological diagnosis is important in the management of VAP, since early diagnosis can 
influence clinical outcomes. The usual methods for microbiological diagnosis are based on 
quantitative or semiquantitative culture, but the results can take 48 h or more to be available. 
The Gram stain method has been used as screening of infection and to guide initial anti-
biotic therapy. However, utility of microscopy examination of respiratory secretions is still 
controversial.
Molecular methods can also be used to obtain results more quickly and initiate rational anti-
biotic therapy of patients with VAP. Many method formats are available for the detection of 
target genes for microbial identification and also for the detection of antimicrobial resistance 
genes.
6.1. Culture
Semiquantitative culture of endotracheal aspirates (ETA) is the recommended microbiologi-
cal procedure to diagnose VAP, since it is more sensitive and can be done more rapidly. 
Other biological specimens have been used, including the ones obtained by invasive sam-
pling, such as: bronchoalveolar lavage (BAL), blind bronchial sampling (mini-BAL), and pro-
tected specimen brush (PSB). Blood cultures should also be performed for all patients with 
suspected VAP. In all cases, samples should be obtained before the patients initiate antibiotic 
therapy [61].
The main problem with the semiquantitative culture of ETA is that its high sensitivity pro-
motes the unnecessary prescription of antibiotics to some patients. In the case of quantita-
tive cultures of lower respiratory tract secretions, the following threshold cut-offs are usually 
applied to diagnosis true infection: ETA 105–106, BAL 104, and PSB 103 CFU/mL. This strategy 
may lead to false-negative results and worse clinical outcomes in some patients [61].
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6.2. Gram stain
The Gram stain of respiratory specimens can provide rapid information regarding morpho-
logical aspects of the bacterial pathogen and whether it is Gram-positive or Gram-negative. 
Additionally, microscopic examination may reveal whether the smear is suggestive of infec-
tion. It is generally accepted as active infection when the biological sample has more than 25 
neutrophils and less than 10 epithelial cells per 10× low-power field.
A decision strategy based on the results of Gram stain was proposed to assist the clinician in 
the empirical prescription of antibiotics [68]:
• If the Gram stain of the ETA is negative: Antibiotic prescription can wait until the micro-
biological culture result is available, since it is very unlikely that the patient have VAP.
• If the Gram stain of PSB is positive: The antibiotic therapy can be initiated and based on 
the result of Gram stain, since it is very likely that the patient has VAP. Later, it can be ad-
justed according to the culture result.
• If the Gram stain of PSB is negative and the Gram stain of the ETA is positive: The 
antibiotic therapy may only be initiated depending on the severity of the patient's clinical 
condition or when the VAP is confirmed by the culture.
Nevertheless, the utility of Gram staining in the diagnosis of VAP and as a guide for the anti-
biotic empirical therapy of VAP is a very controversial subject. It is usually accepted that this 
old diagnostic tool has a high negative predictive value, i.e., VAP is unlikely with a negative 
Gram stain [69].
6.3. Molecular methods
Several molecular-based methods have been proposed for the detection of respiratory patho-
gens that offer a reliable diagnosis, with high sensitivity and specificity. Most of them are 
nucleic acid-based amplification methods that identify, simultaneously, multiple and specific 
target gene sequences (multiplex assays) of a wide range of bacterial species and resistance 
genes [70, 71].
Considering that the etiology of the VAP is very different from the community-acquired 
pneumonia, some main potential gene targets are mecA gene in S. aureus; bla
VIM
 and bla
IMP
 
genes in P. aeruginosa; bla
OXA
 genes in Acinetobacter spp.; and bla
KPC
 gene in members of the 
Enterobacteriaceae family, in addition to the detection of Stenotrophomonas maltophilia [72].
Currently, a variety of platforms or systems are available to identify respiratory pathogens 
using distinct technologies. Some molecular diagnostic systems detect a small number of 
microorganisms, such as GeneXpertMRSA/SA that detects MRSA and MSSA. On the other 
hand, IRIDICA and MALDI-TOFI can detect a wide range of pathogens and resistance mark-
ers. Table 2 shows the major commercial systems available to detect respiratory pathogens, 
including bacteria, viruses, and fungi.
Depending on the methods, the advantages of molecular methods include rapid results; 
detection of very low amounts of gene sequences; target sequences to identify the agent and/
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or the resistance gene markers; possibility to search for multiple agents and resistance mark-
ers; direct detection in clinical specimens; and higher sensitivity. On the other hand, among 
important drawbacks are: most of them are qualitative, risk of contamination, high costs, and 
lack of validation.
6.4. Exhaled breath metabolomics
Recent advances in diagnostic technologies have pointed to metabolomics as an emerging and 
faster method to aid in the diagnosis of various diseases, such as cancer, asthma, among  others. 
The procedure can be performed with samples such as plasma and also with  noninvasive 
samples, such as exhaled air and saliva. Results can return within a matter of hours, com-
pared with days of conventional culture. In the case of exhaled air, the method consists in 
determining the profile of volatile organic compounds (VOCs) emitted by the patient through 
respiration [73]. These metabolic degradation products present in the expired air are derived 
from the patient and the pathogen. The VOC profile is detected through sensitive procedures 
such as nuclear magnetic resonance spectroscopy [74] and gas chromatography-mass spec-
trometry [75]. Studies in patients with VAP have allowed the determination of distinct VOC 
patterns in clinical cases associated to different pathogens, showing good correlation with the 
microbiological culture and offer great potential as biomarkers [76, 77].
Systems No. of pathogens/markers Technology
Abbot IRIDICA System 780 bacteria, 200 fungi, 13 viruses, and 4 
resistance markers
PCR/ESI-MS
Accelerate PhenoTest™ BC kit 27 bacteria and 2 yeasts and AST FISH
Amplidiag® CarbaR+VRE 5 carbapenemase and 2 vancomycin-resistance 
markers
Multiplex RT-PCR
CE-IVD HAI BioDetection kit 12 most common nosocomial pathogens and 
15 resistance markers
NSG
Curetis Unyvero™ 16 bacteria, 1 fungus, 18 resistance markers PCR
FilmArray® Respiratory Panel 17 viruses and 3 bacteria Multiplex RT-PCR
FTD Bacterial pneumoniae HAP Detection and quantification of K. pneumoniae 
and P. aeruginosa
Multiplex RT-PCR
GeneXpertMRSA/SA Only MRSA and MSSA RT-PCR
MALDI-TOFI Wide spectrum of bacteria and fungi MS
NxTAG® Respiratory Pathogen Panel 18 viruses and 3 bacteria Multiplex RT-PCR
R-Biopharm RIDA® GENE-kits mecA/mecC, SCCmec cassette, and S. aureus Multiplex RT-PCR
Verigene® Respiratory Pathogens Flex Test Up to 13 viruses and 3 bacteria (customized) Multiplex RT-PCR
AST: antimicrobial susceptibility testing; FISH: fluorescence in-situ hybridization; MALDI-TOF: matrix-assisted laser 
desorption/ionization time-of-flight; MRSA: methicillin resistant S. aureus; MSSA: methicillin sensitive S. aureus; MS: 
mass spectrometry; NGS: next-generation sequencing; PCR: polymerase chain reaction; PCR/ESI-MS: PCR-electrospray 
ionization mass spectrometry; RT-PCR: real time-PCR.
Table 2. Commercial molecular systems for detection of respiratory pathogens and resistance markers.
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Major drawbacks of this method include: (i) the sampling methodology, which should 
enable to sample from beyond the endotracheal tube and hence to exclude air from the 
upper respiratory tract; (ii) discovery of more pathogen-specific metabolites; and (iii) the 
need of trained personnel to operate the analytical methodology by gas chromatography-
mass spectrometry apparatus.
7. Final considerations
One of the main problems of VAP is the lack of a gold standard for rapid and reliable diagnosis. 
Mortality associated with VAP remains high, mainly because of the increasing prevalence of 
MDR pathogens and their resistance profiles vary depending on the patient group and the hos-
pital setting. However, significant progress has been obtained in the development of systems 
or platforms for molecular detection of respiratory pathogens, which are feasible to be applied 
to the routine diagnosis of VAP. Additionally, metabolic profiling of exhaled breath will aim 
to speed up the process after refinement of the sampling methodology and discovery of highly 
discriminatory biomarkers. With the validation and implementation of these methods for 
diagnosis, probably a more adequate control of VAP will be obtained. Especially, because the 
early and appropriate use of antibiotics may result in reduced mortality among patients under 
mechanical ventilation. Although, it is important to observe the guidelines for patient manage-
ment, antibiotic therapy must be based on local prevalence and microbiology data.
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